B019 for relapsed or refractory B-cell acute lymphoblastic leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new treatment called B019 for people whose B-cell acute lymphoblastic leukemia has come back or not responded to standard therapy. The treatment targets specific proteins on the cancer cells to help your immune system fight the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your leukemia must have come back or not responded to treatment (relapsed or refractory).
- Your leukemia cells must have a protein called CD19 or CD22 (your doctor can test for this).
- Your liver, kidneys, lungs, and heart must be working well enough.
- You must be expected to live longer than 3 months.
- You must agree to use highly effective birth control for 1 year after the study infusion, and not donate eggs or sperm.
- You cannot have active cancer in your brain or spinal cord, or have had certain prior treatments like CAR-T therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
This trial tests a new type of CAR-T cell therapy that is engineered to be more effective against a specific kind of leukemia (B-ALL) that has returned or not responded to treatment. The therapy uses a patient's own immune cells to target and destroy cancer cells.
This trial tests a new type of immune cell therapy (CAR-T) that targets two proteins on cancer cells—CD19 and CD22—to treat lymphoma or leukemia that has come back or not responded to standard treatment. It aims to see if this two-target approach works better.
This study tests an investigational treatment called B019 for people with relapsed or refractory B-cell non-Hodgkin's lymphoma. It aims to see if this treatment can help when other treatments haven't worked.
This trial tests a new type of immunotherapy called CAR-T cells, which are made from your own blood cells and trained to find and destroy leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new type of immunotherapy called CAR-T cell therapy that targets a protein (CD19) on cancer cells. It is for people with B-cell leukemia or lymphoma that has not responded to standard treatment or has come back, and the goal is to help their immune system fight the cancer.
Hear when a new Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.